Roth Capital


Roth Capital Gets Bullish on Cempra Inc (CEMP) Following Phase 3 Trial Success

Cempra Inc (NASDAQ:CEMP) shares are rising close to 6% today on back of the biotech firm’s reveal that Phase 3 data read-outs in …

Roth Capital’s Focus Pick: Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics Inc (NASDAQ:GBT) shares rose about 9% today after the biopharmaceutical company initiated a Phase 1 trial evaluating GBT440 in healthy volunteers under hypoxic …

Zosano Pharma Corp (ZSAN) Shares Keep Rising on Back of Positive Momentum for M207

Zosano Pharma Corp (NASDAQ:ZSAN) shares skyrocketed over 170% in the past three days, after the company reported positive pivotal trial data for its M207 migraine …

NVIDIA Corporation (NVDA) Stock: On Course But Fully Valued

NVIDIA Corporation (NASDAQ:NVDA) is on course to deliver outstanding earnings this coming Thursday, according to Roth Capital analyst Brian Alger. The analyst points out that his meetings …

Roth Capital Upgrades Glu Mobile Inc. (GLUU) Ahead of Earnings

As a sign of confidence in Glu Mobile Inc. (NASDAQ:GLUU), Roth Capital analyst Darren Aftahi is upgrading the stock from Neutral to Buy, while …

Roth Capital Gets Bullish and Boosts Price Target on xG Technology Inc (XGTI); Shares Rise 4%

xG Technology Inc (NASDAQ:XGTI) shares are rising 4% on back of Roth Capital analyst William Gibson‘s new bullish stance on the tech firm. …

Top Analyst: Super Micro Computer, Inc. (SMCI) Appears Back On Growth Trajectory

Roth Capital’s top analyst Brian Alger is out this morning with a new research note on Super Micro Computer, Inc. (NASDAQ:SMCI), after the high-end server maker posted …

Halcon Resources Corporation (HK) on Roth Captial Spotlight Following Recent Acquisitions

Roth Capital analyst John M. White reiterated a Buy rating on shares of Halcon Resources Corporation (NYSE:HK) with a price target of $14, …

Roth Capital Pounds The Table On Palatin Technologies, Inc. (PTN)

Roth Capital analyst Michael Higgins was out pounding the table on shares of Palatin Technologies, Inc. (NYSEMKT:PTN) Tuesday, resuming coverage with a Buy rating and a …

Roth Capital Raises Price Target for Synergy Pharmaceuticals Inc

Late last week, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced the FDA approval of its lead drug Trulance (plecanatide) for the treatment of adults with …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts